3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
https://www.zacks.com/stock/news/2202284/3-reasons-to-retain-nevro-nvro-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202284
Dec 26, 2023 - Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
0
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
https://www.zacks.com/stock/news/2205758/here-s-why-you-should-retain-myriad-genetics-mygn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205758
Jan 04, 2024 - Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
0
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
https://www.zacks.com/stock/news/2205741/enovis-enov-to-strengthen-portfolio-via-its-latest-buyout?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205741
Jan 04, 2024 - Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
0
Here's Why You Should Retain Accuray (ARAY) Stock for Now
https://www.zacks.com/stock/news/2207061/here-s-why-you-should-retain-accuray-aray-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2207061
Jan 08, 2024 - The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
0
SenesTech's (SNES) New Partnership to Broaden Evolve's Scope
https://www.zacks.com/stock/news/2207539/senestech-s-snes-new-partnership-to-broaden-evolve-s-scope?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207539
Jan 09, 2024 - The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.
0
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
https://www.zacks.com/stock/news/2212771/reasons-to-retain-dexcom-dxcm-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212771
Jan 19, 2024 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
Why Integer (ITGR) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2213450/why-integer-itgr-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2213450
Jan 22, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
https://www.zacks.com/stock/news/2215940/angiodynamics-ango-new-xl-catheter-to-help-in-pad-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2215940
Jan 25, 2024 - AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.
0
Bruker (BRKR) to Advance in Lab Automation With New Buyout
https://www.zacks.com/stock/news/2217266/bruker-brkr-to-advance-in-lab-automation-with-new-buyout?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2217266
Jan 29, 2024 - This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."
0
Here's Why You Should Retain Neogen (NEOG) Stock for Now
https://www.zacks.com/stock/news/2218223/here-s-why-you-should-retain-neogen-neog-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2218223
Jan 30, 2024 - Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.
0